Filing Details

Accession Number:
0001209191-21-019275
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-09 19:38:11
Reporting Period:
2021-03-05
Accepted Time:
2021-03-09 19:38:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1468534 John Trizzino C/O Novavax, Inc.
21 Firstfield Road
Gaithersburg MD 20878
Evp, Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-05 417 $27.60 704 No 4 M Direct
Common Stock Acquisiton 2021-03-05 521 $46.00 1,225 No 4 M Direct
Common Stock Acquisiton 2021-03-05 2,083 $5.95 3,308 No 4 M Direct
Common Stock Disposition 2021-03-05 72 $150.31 3,236 No 4 S Direct
Common Stock Disposition 2021-03-05 150 $152.39 3,086 No 4 S Direct
Common Stock Disposition 2021-03-05 312 $153.24 2,774 No 4 S Direct
Common Stock Disposition 2021-03-05 185 $154.00 2,589 No 4 S Direct
Common Stock Disposition 2021-03-05 135 $155.64 2,454 No 4 S Direct
Common Stock Disposition 2021-03-05 160 $157.08 2,294 No 4 S Direct
Common Stock Disposition 2021-03-05 101 $159.02 2,193 No 4 S Direct
Common Stock Disposition 2021-03-05 172 $160.82 2,021 No 4 S Direct
Common Stock Disposition 2021-03-05 162 $163.53 1,859 No 4 S Direct
Common Stock Disposition 2021-03-05 263 $166.48 1,596 No 4 S Direct
Common Stock Disposition 2021-03-05 167 $167.73 1,429 No 4 S Direct
Common Stock Disposition 2021-03-05 91 $168.89 1,338 No 4 S Direct
Common Stock Disposition 2021-03-05 336 $170.25 1,002 No 4 S Direct
Common Stock Disposition 2021-03-05 314 $171.23 688 No 4 S Direct
Common Stock Disposition 2021-03-05 203 $172.24 485 No 4 S Direct
Common Stock Disposition 2021-03-05 186 $173.54 299 No 4 S Direct
Common Stock Disposition 2021-03-05 12 $175.16 287 No 4 S Direct
Common Stock Acquisiton 2021-03-05 383 $5.95 670 No 4 M Direct
Common Stock Disposition 2021-03-05 14 $174.84 656 No 4 D Direct
Common Stock Disposition 2021-03-05 179 $174.84 477 No 4 F Direct
Common Stock Disposition 2021-03-09 190 $168.09 287 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 D Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-03-05 417 $0.00 417 $27.60
Common Stock Stock Option (Right to Buy) Disposition 2021-03-05 521 $0.00 521 $46.00
Common Stock Stock Option (Right to Buy) Disposition 2021-03-05 2,083 $0.00 2,083 $5.95
Common Stock Stock Appreciation Right Disposition 2021-03-05 383 $0.00 383 $5.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,175 2027-12-15 No 4 M Direct
11,465 2028-12-13 No 4 M Direct
64,584 2029-09-26 No 4 M Direct
11,884 2029-09-26 No 4 M Direct
Footnotes
  1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.31 to $150.32, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  3. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.73 to $152.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.785 to $153.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  5. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.88 to $154.72, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  6. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.99 to $155.87, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  7. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.46 to $157.43, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  8. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.50 to $159.35, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  9. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.59 to $161.18, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  10. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.12 to $163.94, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  11. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.21 to $166.98, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  12. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.29 to $167.87, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  13. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.75 to $169.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  14. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.75 to $170.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  15. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.76 to $171.57, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  16. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.81 to $172.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  17. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.82 to $173.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  18. The reporting person received 190 shares of common stock upon the net exercise of 383 stock appreciation rights. The reporting person forfeited 14 shares of common stock underlying the stock appreciation rights representing the base value and 179 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 5, 2021 of $174.84.
  19. Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
  20. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
  21. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
  22. Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.